GPP
RNAC icon

Great Point Partners’s Cartesian Therapeutics RNAC Stock Holding History

Great Point Partners’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-200,000
Closed -$3.22M – 31
2024
Q3 		$3.22M Buy
+200,000
New +$3.12M 0.95% 28
2018
Q1 		– Sell
-5,930
Closed -$1.75M – 42
2017
Q4 		$1.75M Sell
5,930
-24,132
-80% -$10.5M 0.3% 36
2017
Q3 		$16.5M Sell
30,062
-1,188
-4% -$632K 3.2% 14
2017
Q2 		$18.6M Buy
+31,250
New +$13.8M 3.34% 13

Other funds holding RNAC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Great Point Partners's RNAC Position: Q4 2024 in Review

Great Point Partners sold out of Cartesian Therapeutics (RNAC) in Q4 2024, closing a stake of 200,000 shares — an estimated $3.22M sold.

Great Point Partners first reported a position in RNAC in Q2 2017 and held it in 4 quarters. The position peaked at $18.6M in Q2 2017. 68 funds tracked by Wall St. Rank hold RNAC as of Q4 2024.

  • Great Point Partners reported no remaining Cartesian Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Great Point Partners sold 200,000 Cartesian Therapeutics shares in Q4 2024, an estimated $3.22M.
  • Great Point Partners first reported a position in Cartesian Therapeutics in Q2 2017 and held it in 4 quarters.
  • Great Point Partners's Cartesian Therapeutics position peaked at $18.6M in Q2 2017.
  • 68 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2024.

Based on Great Point Partners's 13F filing for Q4 2024, filed 14 Feb 2025.